Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05971589 | A Clinical Study on LM103 Injection for the Treatment of Advanced Solid Tumors | unknown | Early Phase 1 | 5 | Suzhou BlueHorse Therapeutics Co., Ltd.INDUSTRY | 0 | Aug 2, 2023 | clinicaltrials |
| NCT05972460 | IMM2510, a PD-L1 and VEGF Bispecific Fusion Protein, in Patients With Advanced Solid Tumors | unknown | Phase 1 | 108 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc.OTHER | 1 | Aug 2, 2023 | clinicaltrials |
| NCT03284502 | HM95573 in Combination With Either Cobimetinib or Cetuximab in Patients With Locally Advanced or Metastatic Solid Tumors | unknown | Phase 1 | 148 | Hanmi Pharmaceutical Company LimitedINDUSTRY | 1 | Aug 1, 2023 | clinicaltrials |
| NCT04250948 | Efficacy of Perioperative Chemotherapy Plus PD-1 Antibody in the Locally Advanced Gastric Cancer | unknown | Phase 2 | 108 | Sun Yat-sen UniversityOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT05884801 | Phase I Study of QLS1103 in Subjects With Advanced Solid Tumors | unknown | Phase 1 | 148 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 1, 2023 | clinicaltrials |
| NCT04856150 | A Study of Q-1802 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 66 | QureBio Ltd.INDUSTRY | 1 | Jul 27, 2023 | clinicaltrials |
| NCT05226468 | An Early Phase Study of NEI-01 in Patients With Solid Tumors or Acute Myeloid Leukemia | unknown | Phase 1 | 24 | New Epsilon Innovation LimitedINDUSTRY | 1 | Jul 27, 2023 | clinicaltrials |
| NCT05021367 | A Clinical Study of TQB3823 in Patients With Advanced Malignant Tumor | unknown | Phase 1 | 164 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jul 24, 2023 | clinicaltrials |
| NCT05886374 | A Study of HMPL-415S1 in Patients With Advanced Malignant Solid Tumors | unknown | Phase 1 | 81 | HutchmedINDUSTRY | 1 | Jul 21, 2023 | clinicaltrials |
| NCT05396339 | A Clinical Trial to Evaluate the Effect of IAE0972 in Patients With Advanced Malignant Solid Tumors. | unknown | Phase 1 / Phase 2 | 120 | SUNHO（China）BioPharmaceutical CO., Ltd.INDUSTRY | 1 | Jul 19, 2023 | clinicaltrials |
| NCT05173805 | Phase I Clinical Study of YL-15293 in Patients With Advanced Solid Tumor With KRAS Mutation | unknown | Phase 1 / Phase 2 | 150 | Shanghai YingLi Pharmaceutical Co. Ltd.INDUSTRY | 1 | Jul 18, 2023 | clinicaltrials |
| NCT05949775 | Clinical Study of mRNA Vaccine in Patients With Advanced Malignant Solid Tumors | unknown | N/A | 20 | Stemirna TherapeuticsINDUSTRY | 0 | Jul 18, 2023 | clinicaltrials |
| NCT05950815 | A Study of PM1015 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 20 | Biotheus Inc.INDUSTRY | 1 | Jul 18, 2023 | clinicaltrials |
| NCT05944185 | Phase I/II Study of αPD1-MSLN-CAR T Cells in MSLN-positive Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 42 | Shanghai Cell Therapy Group Co.,LtdINDUSTRY | 1 | Jul 14, 2023 | clinicaltrials |
| NCT05941936 | A Clinical Study on LM103 for the Treatment of Advanced Solid Tumors | unknown | Early Phase 1 | 5 | Suzhou BlueHorse Therapeutics Co., Ltd.INDUSTRY | 1 | Jul 12, 2023 | clinicaltrials |
| NCT05942378 | A Study of HRXG-K-1939 and Adebrelimab in Patients With Advanced Solid Tumors | unknown | Phase 1 | 30 | Fudan UniversityOTHER | 1 | Jul 12, 2023 | clinicaltrials |
| NCT05940181 | A Safety and Efficacy Study of XH001 Combined With Sintilimab Injection in Advanced Solid Tumors | unknown | N/A | 9 | jianming xuOTHER | 1 | Jul 11, 2023 | clinicaltrials |
| NCT05798533 | Neo-T in Treating Patients With Advanced Solid Tumors(GI-NeoT-03) | unknown | Phase 1 | 6 | BGI, ChinaOTHER | 1 | Jul 10, 2023 | clinicaltrials |
| NCT05934539 | ALG.APV-527 First-in-human Study | unknown | Phase 1 / Phase 2 | 56 | Aptevo TherapeuticsINDUSTRY | 1 | Jul 7, 2023 | clinicaltrials |
| NCT05933668 | Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Solid Tumor | unknown | Phase 1 | 11 | Peking UniversityOTHER | 1 | Jul 6, 2023 | clinicaltrials |
| NCT05924906 | A Dose Escalation and Expansion Study of NB002 in Participants With Advanced or Metastatic Solid Tumors | unknown | Phase 1 | 30 | Suzhou Neologics Bioscience Co., Ltd.INDUSTRY | 0 | Jul 3, 2023 | clinicaltrials |
| NCT05821595 | JYB1907 in Subjects With Advanced Solid Tumors | unknown | Phase 1 | 30 | JemincareINDUSTRY | 0 | Jun 27, 2023 | clinicaltrials |
| NCT05915481 | Stereotactic Body Radiotherapy Combined With Cadonilimab for Advanced Refractory Malignant Solid Tumors(SCARCE) | unknown | Phase 1 / Phase 2 | 60 | Peking University Third HospitalOTHER | 1 | Jun 23, 2023 | clinicaltrials |
| NCT05911984 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetic Properties and Preliminary Efficacy of 9MW3811 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 27 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 1 | Jun 22, 2023 | clinicaltrials |
| NCT05268666 | A Study of Orally Administered JBI-802, an LSD1/HDAC6 Inhibitor, in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 126 | Jubilant Therapeutics Inc.INDUSTRY | 1 | Jun 15, 2023 | clinicaltrials |
| NCT05904457 | A Phase II Stydy of Bevacizumab Plus Erlotinib in Patients for Krebs Cycle Altered Cancer(BRISK) | unknown | Phase 2 | 32 | Asan Medical CenterOTHER | 1 | Jun 15, 2023 | clinicaltrials |
| NCT05747339 | A Clinical Study on the Efficacy and Mechanism of Tumor Treatment Vaccine (TTV) for Recurrent and Refractory Advanced Solid Tumors | unknown | N/A | 50 | Wuxi People's HospitalOTHER | 0 | Jun 13, 2023 | clinicaltrials |
| NCT05895370 | HPV-T in HPV-16 Positive Recurrent or Metastatic Solid Tumors(GI-HPVT-01) | unknown | Phase 1 | 12 | BGI, ChinaOTHER | 1 | Jun 8, 2023 | clinicaltrials |
| NCT05780307 | IMM2520, a PD-L1 and CD47 Bispecific Antibody in Patients With Advanced Solid Tumors | unknown | Phase 1 | 48 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc.OTHER | 1 | Jun 7, 2023 | clinicaltrials |
| NCT05869240 | BPB-101 in Subjects With Metastatic or Locally Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 388 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jun 6, 2023 | clinicaltrials |
| NCT05794477 | A Study of SHR-1802 in Combination With Adebrelimab in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 132 | Shanghai Hengrui Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 2, 2023 | clinicaltrials |
| NCT05207787 | Phase Ⅰ/Ⅱ Study of the HS-10365 in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 306 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 1, 2023 | clinicaltrials |
| NCT03781219 | A PhaseI Study of HL-085 Plus Vemurafenib in Solid Tumor With BRAF V600 Mutation | unknown | Phase 1 | 45 | Shanghai Kechow Pharma, Inc.INDUSTRY | 1 | May 31, 2023 | clinicaltrials |
| NCT05862831 | Clinical Study of PM1003 in Phase I/IIa Treatment of Advanced Malignant Solid Tumors | unknown | Phase 1 / Phase 2 | 285 | Biotheus Inc.INDUSTRY | 1 | May 17, 2023 | clinicaltrials |
| NCT05359354 | Safety and Efficacy of Personalized Neoantigen Vaccine in Advanced Solid Tumors | unknown | N/A | 36 | YueJuan ChengOTHER | 1 | May 16, 2023 | clinicaltrials |
| NCT03364400 | Phase 1 Study Evaluating VT1021 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 116 | Vigeo Therapeutics, Inc.INDUSTRY | 1 | May 15, 2023 | clinicaltrials |
| NCT05498519 | A First-in-Human, Phase 1 Study of SY-4798 in Patients With Advanced Solid Tumor | unknown | Phase 1 | 80 | Shouyao Holdings (Beijing) Co. LTDOTHER | 1 | May 11, 2023 | clinicaltrials |
| NCT05843305 | A Study of BPI-452080 in Subjects With Solid Tumors | unknown | Phase 1 | 87 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | May 6, 2023 | clinicaltrials |
| NCT03217669 | Epacadostat (INCB24360) in Combination With Sirolimus in Advanced Malignancy | unknown | Phase 1 | 15 | Chao HuangOTHER | 1 | May 3, 2023 | clinicaltrials |
| NCT05837299 | A Study of IMC008 for Advanced Solid Tumors | unknown | Phase 1 | 18 | Changhai HospitalOTHER | 1 | May 1, 2023 | clinicaltrials |
| NCT05833984 | Safety and Efficacy of IMM01 Plus Tislelizumab in Patients With Advanced Solid Tumors and Lymphomas | unknown | Phase 1 / Phase 2 | 309 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc.OTHER | 1 | Apr 27, 2023 | clinicaltrials |
| NCT05828238 | Positron Emission Tomograph(PET) Imaging Explores the Role of SF-DEVD-2 in Monitoring Tumor Efficacy | unknown | Early Phase 1 | 10 | Affiliated Hospital of Jiangnan UniversityOTHER | 1 | Apr 25, 2023 | clinicaltrials |
| NCT05829616 | A Phase I Study of QLS12004 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 50 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 25, 2023 | clinicaltrials |
| NCT05769075 | A Study of TY-2136b in Patients With Advanced Solid Tumors Harboring ALK, ROS1 or NTRK1-3 Alterations | unknown | Phase 1 | 282 | TYK Medicines, IncINDUSTRY | 1 | Apr 24, 2023 | clinicaltrials |
| NCT05818917 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Evidence of Antitumor Activity of FHND5071 as a Single Agent in Adult Patients With Advanced Solid Tumors | unknown | Phase 1 | 80 | Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 19, 2023 | clinicaltrials |
| NCT04363242 | A Study to Find the MTD of SYN125 in People With Solid Tumors and the MTD of SYN125 With a Fixed Dose of SYN004 in People in Patients With Epithelial Cancers With EGFR Expressions | unknown | Phase 1 | 22 | Synermore Biologics Co., Ltd.INDUSTRY | 1 | Apr 12, 2023 | clinicaltrials |
| NCT04571892 | A Clinical Study to Observe the Safety and Efficacy of ScTIL210 in the Treatment of Malignant Solid Tumors | unknown | Phase 1 / Phase 2 | 58 | Shanghai East HospitalOTHER | 1 | Apr 12, 2023 | clinicaltrials |
| NCT05278364 | Phase I/II Study of SY-5007, a RET Inhibitor, in Patients With RET-altered Advanced Solid Tumor | unknown | Phase 1 / Phase 2 | 184 | Shouyao Holdings (Beijing) Co. LTDOTHER | 1 | Apr 12, 2023 | clinicaltrials |
| NCT05805956 | IMM2902 in Patients With Advanced Solid Tumors Expressing HER2 | unknown | Phase 1 / Phase 2 | 105 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc.OTHER | 1 | Apr 10, 2023 | clinicaltrials |
| NCT05171790 | A Study to Evaluate the Efficacy and Safety of QL1706 Injection in Patients With Solid Tumors | unknown | Phase 1 | 419 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 7, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Aug 2, 2023source: clinicaltrials